Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.60 |
| ▸ | CTSL | P07711 | 5/20 | 0.47 |
| ▸ | CTSB | P07858 | 4/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | CTSH | P09668 | 1/20 | 0.41 |
| ▸ | CASP14 | P31944 | 1/20 | 0.41 |
| ▸ | CASP4 | P49662 | 1/20 | 0.41 |
| ▸ | CASP5 | P51878 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3925553 | 0.79 | KMT2A (0.62) | CTSKCTSLCTSBCTSSNSD2 | |
| SCHEMBL9520355 | 0.73 | CHUK (0.45) | CTSKCTSLCTSBCTSSNSD2 | |
| SCHEMBL6241632 | 0.70 | CTSS (0.68) | CTSKCTSLCTSBCTSSCTSV | |
| SCHEMBL3915825 | 0.70 | CTSK (0.43) | CTSKCTSLCTSBCTSSNSD2 | |
| SCHEMBL24081823 | 0.70 | PDE4D (0.41) | CTSKCHUK | |
| SCHEMBL3450564 | 0.69 | CTSK (0.51) | CTSKCTSLCTSBCTSSNSD2 | |
| SCHEMBL28257145 | 0.68 | CTSK (0.47) | CTSKCTSLCTSBCTSSNSD2 | |
| SCHEMBL22411357 | 0.68 | CTSK (0.42) | CTSKCTSLCTSBCTSSNSD2 | |
| SCHEMBL3453193 | 0.68 | CTSK (0.54) | CTSKCTSLCTSBCTSSNSD2 | |
| SCHEMBL3925590 | 0.68 | CTSK (0.66) | CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227579-A1 | Pteridine Derivatives and their Use as Cathespin Inhibitors | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| EP-2035422-A1 | PTERIDINE DERIVATIVES AND THEIR USE AS CATHESPIN INHIBITORS | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007148064-A1 | PTERIDINE DERIVATIVES AND THEIR USE AS CATHESPIN INHIBITORS | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227579-A1 | Pteridine Derivatives and their Use as Cathespin Inhibitors | CTSB, CTSF, CTSS | CTSK 5/4885CTSL 7/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.